



20th July 2004

The Manager
Company Announcements
Australian Stock Exchange
4th Floor
20 Bridge Street
SYDNEY NSW 2000

Dear Sir,

FerriScan Inventors Recognized for Excellence in Breakthrough Technology

20th July 2004. Resonance Health (ASX:RHT) has today announced the publication of results from a 105-patient trial in the peer-reviewed haematology journal *Blood* which demonstrated the non-invasive FerriScan technology as an effective alternative to liver biopsy for the diagnosis of iron overload in the liver.

The FerriScan test measures iron concentrations in the liver which is necessary for a range of iron loading disorders such as hereditary hemochromatosis, thalassemia, sickle cell disease, aplastic anemia and myelodysplasia.

FerriScan is a non-invasive test utilising magnetic-resonance imaging (MRI) technology to provide a scan of the liver which is subsequently analysed to quantify iron loading using FerriScan's proprietary software. It has significant advantages in terms of accuracy and safety over liver biopsy, which is currently the only definitive diagnosis technique for iron overload. Ferriscan was developed by Resonance's subsidiary Inner Vision Biometrics led by a multi disciplinary team from the University of Western Australia.

FerriScan inventors Tim St. Pierre, Paul Clark and Wanida Chua-anusorn co-authored the manuscript with leading physicians that was pre-published in *Blood* on 15 July 2004. *Blood* is the highest rating international peer reviewed journal in the haematology field. Acceptance for publication in *Blood* adds significant credibility to marketing efforts to clinicians on a global basis, and builds on the outstanding publication history relating to the Ferriscan technology founded in high quality international peer reviewed journals with a more technical focus.

The article can be accessed from: <http://www.bloodjournal.org/cgi/content/abstract/2004-01-0177v1> .

Resonance submitted a file for the approval to market Ferriscan to the Australian Therapeutic Goods Administration in April and is awaiting a response. TGA approval would allow Australian marketing to commence, in addition to activities in the European Union through the reciprocal granting of a European CE Mark.

Further information concerning Resonance Health and FerriScan can be obtained from our web sites at: www.resonancehealth.com www.ferriscan.com

Yours sincerely,



Tony Fitzgerald
Managing Director

| Media and investor relations | Company |
|---|---|
| Rebecca Christie, Buchan (02) 9293 2936 / 0417 382 391 | Tony Fitzgerald, Resonance Health Ltd (08) 9389 5933/0418 903 647 or James Williams, Inner Vision Biometrics Pty Ltd (08) 9380 2732/0409 050 519 |